Continuous vs. Intermittent ADT Therapy
Dr. Myers talks about continuous versus intermittent ADT for PCa. Click here to view.
Continuous vs. Intermittent ADT Therapy Read More »
June 2012 Newsletter
The June 2012 Newsletter is available by clicking here Some of the content: Wake Up call Breakfast Dr. Uri Lindner at July 25, 2012 Scotiabank Awareness Night Two Dieticians speaks at March Scotiabank Awareness Night Dr. Singal speaks at May Scotiabank Awareness Night Meet Philip Ng PCCN Conference – Regina Words from Ken Hunter PCCN-Toronto makes donations to 3 hospitals On-going Projects for 2012 The PCCN-Toronto Board of Directors (including photo)
June 2012 Newsletter Read More »
Raduim-223 Drug Beneficial for Bone Metatasis Patients
Treatment with the investigational drug radium-223 (Alpharadin) is associated with significantly increased overall survival in patients with castration-resistant prostate cancer (CRPC), researchers reported at the American Society of Clinical Oncology 2012 annual meeting. Read More.
Raduim-223 Drug Beneficial for Bone Metatasis Patients Read More »
Cancer on the Brain – Cancer Phobia
I got a call from a friend last year. He had prostate cancer and wanted some help thinking through what to do. He had gone to his doctors for the details about his physical condition. He was calling me for help dealing with the other condition he knew he was facing — excessive fear of this dreaded disease that sometimes does more harm than good, what some have called “cancer phobia.” Read More
Cancer on the Brain – Cancer Phobia Read More »
Survival Better with Continuous ADT
CHICAGO—Intermittent androgen deprivation therapy (ADT) has some quality-of-life (QOL) benefits for men with metastatic prostate cancer (PCa), but overall survival times are inferior to those seen with continuous ADT, according to the findings of a 17-year study (SWOG9346) presented at the American Society for Clinical Oncology 2012 annual meeting. Read More
Survival Better with Continuous ADT Read More »
Protein Marker for Aggressive Prostate Cancer
Prostate cancer protein discovered by scientists could lead to new tests and treatments * The protein is found in aggressive forms of the cancer * Scientist believe they can use the protein as a marker, providing a potential new target for drug treatment Read More
Protein Marker for Aggressive Prostate Cancer Read More »
Focal HIFU
It is hoped the new treatment, which involves heating only the tumours with a highly focused ultrasound, will mean men can be treated without an overnight stay in hospital and avoiding the distressing side effects associated with current therapies. Read more.
VIDEO :Dr. Rajiv Singal “Prostate Cancer Diagnostics: the past, present, and future and the PSA controversy.”
Dr. Rajiv Singal MD, FRCSC Head, Division of Urology, Toronto East General Hospital Lecturer, Department of Surgery, University of Toronto Supervisor, Clinical Endourology and Minimally Invasive Fellowship, Toronto East General Hospital Toronto, Canada Prostate cancer remains a uniquely challenging disease. It is very common and its clinical consequences range from harmless to lethal. The challenge remains to try to distinguish between these two ends of the spectrum. Doing so will allow us to better tailor treatment, to avoid significant side effects when not necessary, and to intervene early when an individual is at risk. CLICK ON THE
5-alpha Reductase and Active Surveillance
5-alpha Reductase Inhibitors Help Prostate Cancer Patients on Active Surveillance Jill Stein Published Online: Monday, May 14, 2012 With reference to Antonio Finelli, MD, University Health Network, Princess Margaret Hospital Click here to view article.
5-alpha Reductase and Active Surveillance Read More »
New Therapies
New Therapies for Prostate Cancer: The Practicalities Jeannette Y. Wick, RPh, MBA Published Online: Tuesday, May 15, 2012 Click here to view article.